Cargando…
Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study
BACKGROUND: ‘Long COVID’ describes persistent symptoms, commonly fatigue, lasting beyond 12 weeks following SARS-CoV-2 infection. Potential causes include reduced mitochondrial function and cellular bioenergetics. AXA1125 has previously increased β-oxidation and improved bioenergetics in preclinical...
Autores principales: | Finnigan, Lucy E.M., Cassar, Mark Philip, Koziel, Margaret James, Pradines, Joel, Lamlum, Hanan, Azer, Karim, Kirby, Dan, Montgomery, Hugh, Neubauer, Stefan, Valkovič, Ladislav, Raman, Betty |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102537/ https://www.ncbi.nlm.nih.gov/pubmed/37223439 http://dx.doi.org/10.1016/j.eclinm.2023.101946 |
Ejemplares similares
-
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease
por: Harrison, Stephen A., et al.
Publicado: (2021) -
ABNORMAL SKELETAL METABOLISM BUT NOT CARDIAC DYSFUNCTION AS A CAUSE FOR FATIGUE POST COVID-19
por: Cassar, Mark Philip, et al.
Publicado: (2023) -
AXA Winterthur
por: Staff Association
Publicado: (2020) -
PARTNERS OFFERS - AXA
por: Staff Association
Publicado: (2022) -
Partners deal - Insurance AXA
por: Staff Association
Publicado: (2022)